These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 28535045)

  • 1. BET Bromodomain Inhibitors with One-Step Synthesis Discovered from Virtual Screen.
    Ayoub AM; Hawk LML; Herzig RJ; Jiang J; Wisniewski AJ; Gee CT; Zhao P; Zhu JY; Berndt N; Offei-Addo NK; Scott TG; Qi J; Bradner JE; Ward TR; Schönbrunn E; Georg GI; Pomerantz WCK
    J Med Chem; 2017 Jun; 60(12):4805-4817. PubMed ID: 28535045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and characterization of bromodomain 2-specific inhibitors of BRDT.
    Yu Z; Ku AF; Anglin JL; Sharma R; Ucisik MN; Faver JC; Li F; Nyshadham P; Simmons N; Sharma KL; Nagarajan S; Riehle K; Kaur G; Sankaran B; Storl-Desmond M; Palmer SS; Young DW; Kim C; Matzuk MM
    Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33637650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains.
    Wang J; Erazo T; Ferguson FM; Buckley DL; Gomez N; Muñoz-Guardiola P; Diéguez-Martínez N; Deng X; Hao M; Massefski W; Fedorov O; Offei-Addo NK; Park PM; Dai L; DiBona A; Becht K; Kim ND; McKeown MR; Roberts JM; Zhang J; Sim T; Alessi DR; Bradner JE; Lizcano JM; Blacklow SC; Qi J; Xu X; Gray NS
    ACS Chem Biol; 2018 Sep; 13(9):2438-2448. PubMed ID: 30102854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent and selective bivalent inhibitors of BET bromodomains.
    Waring MJ; Chen H; Rabow AA; Walker G; Bobby R; Boiko S; Bradbury RH; Callis R; Clark E; Dale I; Daniels DL; Dulak A; Flavell L; Holdgate G; Jowitt TA; Kikhney A; McAlister M; Méndez J; Ogg D; Patel J; Petteruti P; Robb GR; Robers MB; Saif S; Stratton N; Svergun DI; Wang W; Whittaker D; Wilson DM; Yao Y
    Nat Chem Biol; 2016 Dec; 12(12):1097-1104. PubMed ID: 27775716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [1,2,4]triazolo[4,3-a]phthalazines: inhibitors of diverse bromodomains.
    Fedorov O; Lingard H; Wells C; Monteiro OP; Picaud S; Keates T; Yapp C; Philpott M; Martin SJ; Felletar I; Marsden BD; Filippakopoulos P; Müller S; Knapp S; Brennan PE
    J Med Chem; 2014 Jan; 57(2):462-76. PubMed ID: 24313754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Covalent-Fragment Screening of BRD4 Identifies a Ligandable Site Orthogonal to the Acetyl-Lysine Binding Sites.
    Olp MD; Sprague DJ; Goetz CJ; Kathman SG; Wynia-Smith SL; Shishodia S; Summers SB; Xu Z; Statsyuk AV; Smith BC
    ACS Chem Biol; 2020 Apr; 15(4):1036-1049. PubMed ID: 32149490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biased multicomponent reactions to develop novel bromodomain inhibitors.
    McKeown MR; Shaw DL; Fu H; Liu S; Xu X; Marineau JJ; Huang Y; Zhang X; Buckley DL; Kadam A; Zhang Z; Blacklow SC; Qi J; Zhang W; Bradner JE
    J Med Chem; 2014 Nov; 57(21):9019-27. PubMed ID: 25314271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular docking and dynamics simulation study of flavonoids as BET bromodomain inhibitors.
    Raj U; Kumar H; Varadwaj PK
    J Biomol Struct Dyn; 2017 Aug; 35(11):2351-2362. PubMed ID: 27494802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In silico study directed towards identification of novel high-affinity inhibitors targeting an oncogenic protein: BRD4-BD1.
    Tumdam R; Kumar A; Subbarao N; Balaji BS
    SAR QSAR Environ Res; 2018 Dec; 29(12):975-996. PubMed ID: 30411639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and biological evaluation of novel 4-phenylisoquinolinone BET bromodomain inhibitors.
    Bennett MJ; Wu Y; Boloor A; Matuszkiewicz J; O'Connell SM; Shi L; Stansfield RK; Del Rosario JR; Veal JM; Hosfield DJ; Xu J; Kaldor SW; Stafford JA; Betancort JM
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1811-1816. PubMed ID: 29657099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring Selective Inhibition of the First Bromodomain of the Human Bromodomain and Extra-terminal Domain (BET) Proteins.
    Raux B; Voitovich Y; Derviaux C; Lugari A; Rebuffet E; Milhas S; Priet S; Roux T; Trinquet E; Guillemot JC; Knapp S; Brunel JM; Fedorov AY; Collette Y; Roche P; Betzi S; Combes S; Morelli X
    J Med Chem; 2016 Feb; 59(4):1634-41. PubMed ID: 26735842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1,4-Dihydropyridinebutyrolactone-derived ring-opened ester and amide analogs targeting BET bromodomains.
    Jiang J; Zhao PL; Sigua LH; Chan A; Schönbrunn E; Qi J; Georg GI
    Arch Pharm (Weinheim); 2022 Nov; 355(11):e2200288. PubMed ID: 35941525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-based protein stabilization assays for the detection of interactions between small-molecule inhibitors and BRD4.
    Schulze J; Moosmayer D; Weiske J; Fernández-Montalván A; Herbst C; Jung M; Haendler B; Bader B
    J Biomol Screen; 2015 Feb; 20(2):180-9. PubMed ID: 25266565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel BRD4 inhibitors by high-throughput screening, crystallography, and cell-based assays.
    Sun Z; Zhang H; Chen Z; Xie Y; Jiang H; Chen L; Ding H; Zhang Y; Jiang H; Zheng M; Luo C
    Bioorg Med Chem Lett; 2017 May; 27(9):2003-2009. PubMed ID: 28347667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands.
    Hewings DS; Fedorov O; Filippakopoulos P; Martin S; Picaud S; Tumber A; Wells C; Olcina MM; Freeman K; Gill A; Ritchie AJ; Sheppard DW; Russell AJ; Hammond EM; Knapp S; Brennan PE; Conway SJ
    J Med Chem; 2013 Apr; 56(8):3217-27. PubMed ID: 23517011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.
    Rhyasen GW; Hattersley MM; Yao Y; Dulak A; Wang W; Petteruti P; Dale IL; Boiko S; Cheung T; Zhang J; Wen S; Castriotta L; Lawson D; Collins M; Bao L; Ahdesmaki MJ; Walker G; O'Connor G; Yeh TC; Rabow AA; Dry JR; Reimer C; Lyne P; Mills GB; Fawell SE; Waring MJ; Zinda M; Clark E; Chen H
    Mol Cancer Ther; 2016 Nov; 15(11):2563-2574. PubMed ID: 27573426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural variation of protein-ligand complexes of the first bromodomain of BRD4.
    Guest EE; Pickett SD; Hirst JD
    Org Biomol Chem; 2021 Jun; 19(25):5632-5641. PubMed ID: 34105560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
    Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
    Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of potent BET bromodomain 1 stereoselective inhibitors using DNA-encoded chemical library selections.
    Modukuri RK; Yu Z; Tan Z; Ta HM; Ucisik MN; Jin Z; Anglin JL; Sharma KL; Nyshadham P; Li F; Riehle K; Faver JC; Duong K; Nagarajan S; Simmons N; Palmer SS; Teng M; Young DW; Yi JS; Kim C; Matzuk MM
    Proc Natl Acad Sci U S A; 2022 May; 119(22):e2122506119. PubMed ID: 35622893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.
    Law RP; Atkinson SJ; Bamborough P; Chung CW; Demont EH; Gordon LJ; Lindon M; Prinjha RK; Watson AJB; Hirst DJ
    J Med Chem; 2018 May; 61(10):4317-4334. PubMed ID: 29656650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.